An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.
Geoffrey Wu
Advertisement
Geoffrey Wu, PhD*, is a regulatory review officer, [email protected].
Articles by Geoffrey Wu
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Shilpa CDMO to Launch as Dedicated Complex Small-Molecule Contract Development and Manufacturing Brand at CPHI Milan
2
Assessment of Silicone Oil Cleaning on Indirect Surfaces in Aseptic Manufacturing
3
Technology Transfer: Success Drivers and Obstacles Explained
4
PharmTech Weekly Roundup—September 11, 2026
5